From GLP-1s to Gene Therapies: How Global Healthcare Breakthroughs Are Reshaping India's Life Sciences

The pharmaceutical industry has not seen a confluence of breakthroughs this significant since the statins revolution of the 1980s. In a span of three years, GLP-1 receptor agonists have redefined metabolic disease management, CAR-T cell therapies have produced remarkable outcomes in haematological cancers, and CRISPR-based gene editing has moved from laboratory promise to clinical pipeline reality. Each of these developments carries profound implications for Indian life sciences — not as a passive recipient of global innovation, but as an active participant with enormous latent capability and a clear strategic mandate.

The leaders who will define India's next pharmaceutical decade are those who understand these global trajectories deeply enough to make the right bets today. This is not about following innovation. It is about positioning India at the table where the next generation of global healthcare is being shaped.

The GLP-1 Revolution and India's Strategic Moment

The numbers around GLP-1 receptor agonists — semaglutide (Novo Nordisk's Ozempic and Wegovy), tirzepatide (Eli Lilly's Mounjaro) — are almost incomprehensible in their scale. Ozempic alone generated approximately $14 billion in global revenues in 2024. Analysts project the GLP-1 market to exceed $150 billion globally by 2030. The clinical indications are expanding beyond obesity and Type 2 diabetes to cardiovascular disease, non-alcoholic steatohepatitis (NASH), chronic kidney disease, and potentially addiction and Alzheimer's.

For Indian pharma, the GLP-1 opportunity is multidimensional. India has approximately 101 million people with Type 2 diabetes — the largest diabetic population in the world — and an obesity epidemic that is accelerating in urban populations. Novo Nordisk's semaglutide patents will begin expiring from 2026 in some jurisdictions, opening the biosimilar window. Several Indian companies are already in clinical development: Biocon Biologics has semaglutide in its pipeline, and Sun Pharmaceutical has announced a GLP-1 programme. Smaller players like Torrent Pharmaceuticals and Glenmark are evaluating positions.

The strategic question is not whether to pursue GLP-1 biosimilars — for most large Indian pharma companies, this is a given. The question is speed, manufacturing capability, and regulatory strategy. Injectable biologics require fundamentally different manufacturing infrastructure than small molecules. Companies that do not have fill-and-finish capacity and cold chain logistics in place by 2026–2027 will be late to a market where first-mover advantage matters considerably.

"In the GLP-1 race, Indian pharma has a three-year window to build manufacturing leadership. After that, the advantage shifts to whoever has the deepest clinical data package and the strongest regulatory relationships."

CAR-T Therapies: India Moves from Observer to Participant

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents one of the most significant advances in oncology in decades — and also one of the most expensive. Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) are priced at $300,000–$500,000 per treatment course in the United States, placing them entirely beyond the reach of most Indian patients.

The Indian response has been to develop indigenous CAR-T capabilities. ImmunoACT, born from IIT Bombay's research, received CDSCO approval in October 2023 for NexCAR19 — the world's first approved CAR-T therapy developed entirely in a low- and middle-income country. Priced at approximately ₹42 lakh ($50,000), NexCAR19 demonstrated response rates comparable to its Western counterparts in B-cell malignancies at approximately one-sixth the cost.

Immuneel Therapeutics, a Bengaluru-based company, is building an allogeneic (off-the-shelf) CAR-T platform that could further reduce costs. Cipla's CAR-T programme, developed in partnership with ImmunoACT, is advancing through the regulatory pathway. The Tata Memorial Centre, India's premier cancer institution, has become a key clinical trial site for multiple CAR-T candidates.

The leadership challenge in this space is distinctive. CAR-T development sits at the intersection of advanced manufacturing (viral vector production, gene editing, cell processing), complex clinical management (cytokine release syndrome protocols, specialised infusion centres), and regulatory navigation. The leaders who will build India's CAR-T ecosystem need to understand all three — and most importantly, they need to understand the economics of building a sustainable access model that can reach the 1.4 million new cancer patients diagnosed in India each year.

CRISPR and the Gene Editing Pipeline

CRISPR-Cas9 gene editing has moved from Nobel Prize-winning science to clinical reality. Vertex Pharmaceuticals and CRISPR Therapeutics received FDA approval in late 2023 for Casgevy — the first approved CRISPR-based medicine — for sickle cell disease and beta-thalassemia. Both conditions have significant prevalence in India: beta-thalassemia affects approximately 100,000 children born annually, and sickle cell disease is prevalent across tribal populations, with the government declaring it a public health priority under the Sickle Cell Anaemia Mission.

Indian researchers and companies are positioning for the CRISPR opportunity. The CSIR Institute of Genomics and Integrative Biology (IGIB) has active CRISPR research programmes. The Department of Biotechnology's National Biopharmaceutical Mission (under BIRAC) has invested over ₹1,500 crore in advanced biology research, including gene editing. The regulatory framework is still developing — CDSCO has issued draft guidelines on gene therapy products, but the approval pathway for CRISPR-based medicines remains less defined than in the US or EU.

The Biosimilar Opportunity in a Fast-Track FDA Era

India's pharmaceutical sector derives approximately 25% of its export revenues from the United States. The US biosimilars market, now valued at over $30 billion annually, represents the next frontier. India's major pharma players — Biocon, Dr. Reddy's, Cipla, and Lupin — have invested heavily in biologics manufacturing and FDA filing capabilities. Biocon Biologics, with its Viatris partnership, has assembled the most ambitious biosimilar portfolio of any Indian company, with FDA-approved products in insulin, immunology, and oncology.

What is less appreciated is the talent implication. Building an FDA-compliant biologics manufacturing operation requires Vice Presidents of Regulatory Affairs with FDA track records, Quality Directors who have managed FDA pre-approval inspections, and Heads of Analytical Development with deep characterisation expertise. These individuals are among the most sought-after executives in Indian pharma today.

India's Biologics Mission: Policy Meets Ambition

The National Biopharma Mission, with its second phase (NBM-II) investing over ₹3,000 crore through BIRAC, represents the government's recognition that biologics will define the next generation of pharmaceutical value creation. The mission supports pre-clinical and clinical development of biosimilars and novel biologics, builds shared infrastructure through Biopharma Technology Innovation Hubs, and funds academic-industry partnerships at IIT Madras, IISc, and CSIR labs.

The government's Production Linked Incentive scheme for pharmaceuticals specifically includes enhanced incentives for complex biologics and high-value pharmaceuticals. The strategic intent is clear: India aims to move up the value chain from process chemistry generics to complex biologics, and eventually to novel drug discovery.

What This Means for Leaders

The convergence of GLP-1, CAR-T, CRISPR, and the broader biologics revolution creates a strategic inflection point for Indian life sciences that will play out over the next five to eight years. The organisations that move decisively now — investing in manufacturing capability, regulatory expertise, and clinical development partnerships — will define the sector's next chapter. Those that wait for the pathways to be fully proven will find themselves perpetually in catch-up mode.

For CEOs and board members in Indian pharma and biotech, the leadership investment priorities are clear: build regulatory affairs leadership with genuine international depth, attract scientific talent from global pharma into Indian organisations, and cultivate the patient capital mindset that complex biologics development requires. At Gladwin International, we are seeing intense competition for exactly this profile of leader — and the organisations that win this talent war will win the biologics race.